What brain tumors are Vorasidenib indicated for?

Vorasidenib is a small molecule inhibitor that targets IDH1 and IDH2 gene mutations. It is mainly used to treat brain tumors, especially gliomas carrying such gene mutations. IDH1 and IDH2 mutations are more common in patients with low-grade gliomas and some high-grade gliomas. These mutations It will cause cells to produce abnormal metabolite 2-hydroxyglutarate (2-HG), promoting the occurrence and progression of tumors. Vorsidenib blocks the abnormal growth of tumor cells by inhibiting IDH enzyme activity and reducing 2-HG levels.

Voxirinib is mainly suitable for patients with low-grade glioma, especially those cases where IDH1 or IDH2 mutations are detected. Low-grade gliomas generally grow more slowly, but the risk of recurrence and progression remains. Traditional treatments include surgery, radiotherapy and chemotherapy, but the therapeutic effects are limited and the side effects are severe. As a precise targeted drug, Vorsidenib can delay the development of tumors and help improve patients' prognosis and quality of life.

In addition, voroxinib is also being explored for the treatment of some high-grade gliomas, such as glioblastoma (glioblastoma). Although research in this area is still ongoing and has not yet become a standard treatment, vorsidenib provides new possibilities for treatment targeting specific molecular markers. It represents the trend of transition from traditional means to molecular targeted therapy in the treatment of brain tumors.

In general, vorsidenib is mainly targeted at patients with gliomas carrying IDH1/2 mutations, by inhibiting the production of abnormal metabolites and slowing down tumor growth. In the future, with the advancement of more clinical research, vorsidenib is expected to play a more important role in the treatment of brain tumors and become an important part of precision medicine.

Reference materials:https://www.drugs.com/donanemab.html